Heparin-induced thrombocytopenia

Department of Cardiology, Joseph J. Jacobs Center for Vascular Biology, The Cleveland Clinic Foundation, Ohio 44195, USA.

Heparin-induced thrombocytopenia (HIT) is a potentially serious complication of heparin therapy and is being encountered more frequently in patients with cardiovascular disease as use of anticoagulant therapy becomes more widespread. Our understanding of the pathophysiology of this immune-mediated condition has improved in recent years, with heparin-platelet factor 4 complex as the culprit antigen in most patients. New sensitive laboratory assays for the pathogenic antibody are now available and should permit an earlier, more reliable diagnosis, but their optimal application remains to be defined. For patients in whom HIT is diagnosed, immediate discontinuation of heparin infusions and elimination of heparin from all flushes and ports are mandatory. Further management of patients with HIT is problematic at present, as there are no readily available alternative anticoagulant agents in the United States with proven efficacy in acute coronary disease. The direct thrombin inhibitors appear to be the most promising alternatives to heparin, when continued use of heparin is contraindicated, and the results of several multicenter trials evaluating their application in patients with HIT are awaited.

This article has been cited by other articles:

				A. J Ansara, S. Arif, and R. D Warhurst Weight-Based Argatroban Dosing Nomogram for Treatment of Heparin-Induced Thrombocytopenia Ann. Pharmacother., January 1, 2009; 43(1): 9 - 18. [Abstract] [Full Text] [PDF]

				S. P Keegan, E. M Gallagher, N. E Ernst, E. J Young, and E. W Mueller Effects of Critical Illness and Organ Failure on Therapeutic Argatroban Dosage Requirements in Patients with Suspected or Confirmed Heparin-Induced Thrombocytopenia Ann. Pharmacother., January 1, 2009; 43(1): 19 - 27. [Abstract] [Full Text] [PDF]

				W. Kittisupamongkol Incidence and Prognostic Significance of Thrombocytopenia in Patients Receiving Heparin Therapy Arch Intern Med, October 27, 2008; 168(19): 2170 - 2170. [Full Text] [PDF]

				K. W. Phillips, P. P. Dobesh, and S. T. Haines Considerations in using anticoagulant therapy in special patient populations Am. J. Health Syst. Pharm., August 1, 2008; 65(15_Supplement_7): S13 - S21. [Abstract] [Full Text] [PDF]

				A. F. Merry Focus on Thrombin: Alternative Anticoagulants Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2007; 11(4): 256 - 260. [Abstract] [PDF]

				Part 8: Stabilization of the Patient With Acute Coronary Syndromes Circulation, December 13, 2005; 112(24_suppl): IV-89 - IV-110. [Full Text] [PDF]

				C. S. Carr, A. Rayner, J. Ponte, and J. B. Desai Off-Pump Coronary Artery Bypass Grafting in a Heparin-Induced Thrombocytopenia Type II Patient Using Hirudin Ann. Thorac. Surg., February 1, 2005; 79(2): 696 - 698. [Abstract] [Full Text] [PDF]

				P. Kumar, D. A. Hoppensteadt, M. M. Prechel, R. B. Deddish, and J. M. Walenga Prevalance of Heparin-Dependent Platelet-Activating Antibodies in Preterm Newborns After Exposure to Unfractionated Heparin Clinical and Applied Thrombosis/Hemostasis, October 1, 2004; 10(4): 335 - 339. [Abstract] [PDF]

				S. Suzuki, S. Sakamoto, M. Matsuo, C. Shimano, T. Kuroda, and T. Matsuo Thrombotic Complications in Three Hemodialysis Patients With Heparin-Induced Thrombocytopenia Type I Clinical and Applied Thrombosis/Hemostasis, January 1, 2004; 10(1): 81 - 84. [Abstract] [PDF]

				K. W. Cleveland Argatroban: A New Treatment Option for Heparin-Induced Thrombocytopenia Crit. Care Nurse, December 1, 2003; 23(6): 61 - 66. [Full Text] [PDF]

				A. Koster and T. Fischer Management of Patients with Heparin-Induced Thrombocytopenia During Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2003; 7(4): 411 - 416. [Abstract] [PDF]

				J. R. De Palma Delayed-Onset Heparin-Induced Thrombocytopenia Ann Intern Med, November 4, 2003; 139(9): 790 - 790. [Full Text] [PDF]

				F. Collart, D. Derouck, F. Kerbaul, H. Feier, and T. G. Mesana Regression of intracardiac heparin-induced thrombosis after aortic root surgery Ann. Thorac. Surg., August 1, 2003; 76(2): 617 - 619. [Abstract] [Full Text] [PDF]

				E. Pravinkumar and N. R. Webster HIT/HITT and alternative anticoagulation: current concepts Br. J. Anaesth., May 1, 2003; 90(5): 676 - 685. [Abstract] [Full Text] [PDF]

				M. G Reichert, D. A MacGregor, E. H Kincaid, and S. Y Dolinski Excessive Argatroban Anticoagulation for Heparin-Induced Thrombocytopenia Ann. Pharmacother., May 1, 2003; 37(5): 652 - 654. [Abstract] [Full Text] [PDF]

				J. C. Vasquez, A. Vichiendilokkul, S. Mahmood, and F. A. Baciewicz Jr Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery Ann. Thorac. Surg., December 1, 2002; 74(6): 2177 - 2179. [Abstract] [Full Text] [PDF]

				S. K. Young New Treatment Options for Heparin-Induced Thrombocytopenia Journal of Pharmacy Practice, August 1, 2002; 15(4): 305 - 317. [Abstract] [PDF]

				L. G. Y. Claeys Lethal Heparin-Associated Pulmonary Embolism: Case Reports Angiology, July 1, 2002; 53(4): 475 - 478. [Abstract] [PDF]

				J. E. Tcheng, D. J. Kereiakes, A. M. Lincoff, B. S. George, N. S. Kleiman, D. C. Sane, D. B. Cines, R. E. Jordan, M. A. Mascelli, M. A. Langrall, et al. Abciximab Readministration: Results of the ReoPro Readministration Registry Circulation, August 21, 2001; 104(8): 870 - 875. [Abstract] [Full Text] [PDF]

				B. E. Lewis, D. E. Wallis, S. D. Berkowitz, W. H. Matthai, J. Fareed, J. M. Walenga, J. Bartholomew, R. Sham, R. G. Lerner, Z. R. Zeigler, et al. Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia Circulation, April 10, 2001; 103(14): 1838 - 1843. [Abstract] [Full Text] [PDF]

				D. E. Wallis, R. Quintos, W. Wehrmacher, and H. Messmore Safety of Warfarin Anticoagulation in Patients With Heparin-Induced Thrombocytopenia Chest, November 1, 1999; 116(5): 1333 - 1338. [Abstract] [Full Text] [PDF]

				J. F. Vazquez-Jimenez, U. Janssens, B. Sellhaus, B. Hermanns, W. Huegel, P. Hanrath, and B. J. Messmer THROMBOSIS OF A MITRAL VALVE PROSTHESIS IN A PATIENT WITH HEPARIN-INDUCED THROMBOCYTOPENIA TYPE II J. Thorac. Cardiovasc. Surg., October 1, 1999; 118(4): 751 - 753. [Full Text] [PDF]

				D. E. Wallis, B. E. Lewis, H. L. Messmore, R. Pifarre, and J. M. Walenga Inadequacy of Current Prevention Strategies for Heparin-Induced Thrombocytopenia Clinical and Applied Thrombosis/Hemostasis, October 1, 1999; 5(1_suppl): S16 - S20. [Abstract] [PDF]

				J. Fareed, J. M. Walenga, D. A. Hoppensteadt, W. P. Jeske, S. Ahmad, H. Lietz, R. McKenna, H. L. Messmore, and S. Haas Soluble Adhesion Molecules in the HIT Syndrome: Pathophysiologic Role and Therapeutic Modulation Clinical and Applied Thrombosis/Hemostasis, October 1, 1999; 5(1_suppl): S38 - S44. [Abstract] [PDF]

				P. J. Zed, J. E. Tisdale, and S. Borzak Low-Molecular-Weight Heparins in the Management of Acute Coronary Syndromes Arch Intern Med, September 13, 1999; 159(16): 1849 - 1857. [Abstract] [Full Text] [PDF]

				M. W. McClure, S. D. Berkowitz, R. Sparapani, R. Tuttle, N. S. Kleiman, L. G. Berdan, A. M. Lincoff, J. Deckers, R. Diaz, K. R. Karsch, et al. Clinical Significance of Thrombocytopenia During a Non–ST-Elevation Acute Coronary Syndrome : The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Experience Circulation, June 8, 1999; 99(22): 2892 - 2900. [Abstract] [Full Text] [PDF]